A block-randomized , single-blind , placebo-controlled phase I trial HIV-CORE @ administered for the first time candidate HIV-@ - vaccines or placebo to @ healthy HIV-@ / @-uninfected adults in Oxford , UK and elicited high frequencies of HIV-@-specific T cells capable of inhibiting HIV-@ replication in vitro .